AbbVie stock holds near its 52-week high
Published on 09/19/2026 at 11:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AbbVie Inc. (ISIN US00287Y1091) stock traded at USD 263.52 on September 19, 2026, putting it close to its 52-week high of USD 267.47 and above the 52-week low of USD 190.75.
Second-quarter numbers set the tone
According to finanzen.ch on September 18, 2026, AbbVie rose 0.3 percent to USD 264.80 in New York trading, and the session volume reached 1,022,150 shares. The same report said the stock touched an intraday high of USD 266.29 and opened at USD 263.29.
That article also said AbbVie posted adjusted earnings per share of USD 2.03 on July 31, 2026, versus USD 0.52 a year earlier, while revenue rose 10.16 percent to USD 16.99 billion from USD 15.42 billion. The next reported quarter is due on October 23, 2026, according to the same source.
Analysts still lean positive
According to Pintu on September 18, 2026, the consensus among 31 analysts stood at USD 277.31, which is 5.64 percent above the current price and within a range from USD 200 to USD 328. The same piece described the stock as Buy, which leaves room for debate after the recent run toward the yearly peak.
On the same date, GuruFocus said the GF Value for ABBV was USD 220.69, while the market price was USD 264.02, implying 19.6 percent overvaluation. For investors, that gap is the cleanest counterpoint to the bullish analyst average.
Near the yearly peak
AbbVie stock closed at USD 263.52 on September 19, 2026, with market capitalization at USD 466.34 billion and volume at 8.18 million shares. The 52-week range of USD 190.75 to USD 267.47 shows the shares trading only a little below the top of that band.
AbbVie stock key data
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- Ticker: ABBV
- Trading venue: NYSE
- Price (as of September 19, 2026): USD 263.52
- Market capitalization: USD 466.34 billion
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: S&P 500
